UPFRONT BRIEFING
Blackstone is writing Pfizer a cheque for up to $1.5B to help fund berobenatide, the monthly GLP-1 Pfizer paid $10B for Metsera to own. Private equity as an R&D budget line is now standard big-pharma kit; this one just comes in an obesity-sized portion.
Elsewhere, Reuters says the FDA's commissioner voucher fast lane is shelved (the agency says it isn't), and Regeneron put up Phase 2 POTS data for a first-in-class antibody. Diary: Summit's ivonescimab PDUFA lands Saturday, Jefferies London opens Monday, and Heidi Overton's HELP committee vote is Wednesday.
In case you missed it: Our breakdown of 2026's biotech licensing deals shows China-origin assets taking two-thirds of the year's headline value, and how little of it is paid upfront. Read the breakdown →
TAPE ACTION

Biotech sold off well beyond healthcare: XBI (3.3%), NBI (2.3%) and BBC (4.6%) against XLV (0.6%) and the S&P 500 (0.4%), on a day small caps lagged across the board with the Russell 2000 down 1.7%.
Nvidia fell 4.3% after Jensen Huang resigned as CEO effective immediately (CFO Colette Kress is interim), having been down as much as 14% early before AMD (+5.9%, William Blair upgrade) and Broadcom (+5.5%) led the recovery. The 10-year yield rose about 12bp to 5.10% with a December hike fully priced; Brent +3.3% to $95.82. NDX (0.3%), Dow (0.4%); October PPI is due at 8:30 ET today.
THE BIG 3
1️⃣ — Blackstone commits up to $1.5B to Pfizer's monthly obesity shot
Blackstone Life Sciences commits up to $1.5B, phased through 2028, to co-fund Pfizer's berobenatide (PF'3944, ex-Metsera MET-097), a once-monthly GLP-1 with up to 10 Phase 3 trials ongoing or planned; Pfizer pays milestones on FDA approval as a monthly single agent for weight management and on sales goals, distributed over multiple years.
Why it matters: Pfizer is renting a balance sheet for the most expensive bet in its pipeline. It paid $10B for Metsera after a bidding war with Novo, and up to 10 Phase 3 studies, possibly including head-to-heads against Zepbound and Wegovy, is the kind of spend that hits EPS just as Eliquis and Ibrance lose exclusivity. Leerink's David Risinger calls the deal positive for the income statement and cash flow over the next two years. Blackstone is paid only on a once-monthly monotherapy approval plus sales hurdles, so its money backs the dosing interval, not GLP-1 as a class. Blackstone has run this play with Alnylam (up to $2B), Moderna flu ($750M) and Merck ($700M); Pfizer's cost is undisclosed milestone drag on future sales.
Source: Endpoints
More: Fierce Biotech; BioPharma Dive; STAT; BioSpace
2️⃣ — Commissioner's voucher program reported shelved as FDA insists it is still running
Reuters reported the FDA has shelved the Commissioner's National Priority Voucher (CNPV) program Makary launched in June 2025 to cut reviews to 1-2 months; no new vouchers have been awarded since he left about six months ago, the political-appointee council overseeing reviews has gone dormant, and the agency also appears to have paused publishing complete response letters. FDA says CNPV is still running: 22 drugs hold vouchers, 12 are approved.
Why it matters: The tell is the price of the old-fashioned alternative. BioNTech paid $205M cash for Scholar Rock's rare pediatric PRV on Tuesday, and with CNPV dormant, tradeable vouchers are the only reliable way left to buy a faster review. That supports PRV sellers and raises the cost of a quick launch for everyone else. For the 10 voucher holders still awaiting action, the risk is reverting to standard clocks at an agency with more than 1,000 open jobs. CNPV was always political: critics said it rewarded companies that met White House pricing demands. Pausing CRL publication also removes one of the few transparency gains of the Makary era. Heidi Overton's HELP committee vote on 18 November decides who inherits both calls.
Source: Endpoints
More: Fierce Pharma; STAT; BioSpace
3️⃣ — Regeneron's first-in-class NPR1 antibody cuts the POTS heart-rate spike in Phase 2
Phase 2 PINNACLE (n=82) tested a single subcutaneous dose of baloncibart in POTS: 450 mg cut the lying-to-standing heart-rate rise vs placebo by 11.4 bpm at day 8 (primary, nominal p=0.0007) and 7.4 bpm at day 29, and improved orthostatic symptoms (-12.9 points) and physical function (-13.8) on the LWPQ; 150 mg's day-8 effect (-9.5 bpm) did not hold. No discontinuations; potentially pivotal Phase 3 planned for 1H27.
Why it matters: POTS has no FDA-approved drug and Regeneron puts US prevalence at 500,000 to several million, mostly young women, so a single-shot biologic that works opens a category rather than taking share. The biology looks on target: NT-proBNP rose while standing norepinephrine and haemoglobin fell, consistent with the plasma-volume expansion NPR1 blockade is meant to deliver. The caveats are size and statistics: 27 or 28 patients per arm, no prespecified hypothesis testing, nominal p-values only, and a 150 mg effect that faded by day 29. Standing systolic pressure rose 8.7 mmHg on 450 mg, useful for an orthostatic patient but worth watching chronically. Phase 3 leans on Regeneron's own LWPQ questionnaire, so FDA buy-in on that endpoint is the swing factor.
Source: Regeneron (BioSpace PR)
EVERYTHING ELSE THAT BROKE
Bristol Myers will merge research and development under CMO Cristian Massacesi from 1 January; research chief Robert Plenge (ex-Celgene) leaves after a transition through March 2027, as Eliquis (more than $14B last year) heads toward its patent cliff. — Fierce Biotech
The FDA has more than 1,000 open jobs, and the staffing shortfall is starting to show in drug reviews. — BioPharma Dive
Taiho completed the US NDA (RTOR) for zipalertinib plus chemo in 1L EGFR exon 20 NSCLC on Phase 3 REZILIENT3's PFS win; partner Cullinan is owed $30M on a 2L and $100M on a 1L US approval. — BioSpace (PR)
The DEA gave Takeda's narcolepsy drug Orzeyful a "lighter" controlled-substance schedule, clearing the way for a first-in-class launch. — Fierce Pharma
Kyverna dropped the next-gen CD19 CAR-T it once pitched as miv-cel's follow-up, while it seeks FDA approval for miv-cel as what could be the first CAR-T for an autoimmune disease. — Fierce Biotech
DEAL FLOW
Track the Deals Shaping Biotech
Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.
M&A / BD&L
Vor Bio added RemeGen's RC298, a long-acting dual BAFF/APRIL TACI-Fc in IND-enabling work, to its ex-Greater China licence for ~$56M upfront ($10M cash plus pre-funded warrants for 2.3M Vor shares, ~$46M) and up to $300M in development milestones; China IND 1H27. — Fierce Biotech
Lineage Cell Therapeutics acquired NeuroAirmid and rights to HUNT1, a stem cell-derived neural cell therapy for Huntington's in the Phase 1b/2a REGEN4HD study (6 dosed), for $4.7M in cash and equity at closing, up to $5M at the first anniversary and up to $48M in milestones. — BioSpace (PR)
VC / PRIVATE FINANCINGS
No notable private biotech financings since yesterday's edition.
IPO / FOLLOW-ON
Windward Bio (WWB) priced its IPO at $17, 10,294,117 shares for $175M, plus a concurrent $50M private placement to Sanofi ($225M in total); WIN378 (ultra-long-acting TSLP antibody, Phase 2/3 asthma) and WIN027 (TSLP x IL-13) are licensed from Kelun/Harbour and Qyuns; Jefferies, TD Cowen, Piper Sandler and UBS; trades today. — BioPharma Dive
Rezera (ex-NodThera) postponed its planned ~$200M IPO shortly before its expected debut. — Endpoints
Vir Biotechnology (VIR) priced a $150M follow-on, 15M shares at $10.00 (+2.25M option); Leerink, Morgan Stanley and Evercore ISI; closes 16 Nov. — BioSpace (PR)
ACADEMIC CORNER
Nature Biotech analyzed AAV gene therapy IND submissions and highlighted common drivers of regulatory holds. — Nature Biotech
Lancet revisited whether chemotherapy is still needed in all dMMR advanced or recurrent endometrial cancer patients. — Lancet
Know someone who'd like this?
Forward it along. It takes ten seconds and means a lot to us.
Have a great weekend. Blackstone is presumably funding ours.
— The BioBucks Team
